卫生技术评估在健康保险和健康管理中的应用

doi:10.6040/j.issn.1671-7554.0.2018.1078

摘要/Abstract

摘要： 卫生技术评估作为重要的卫生决策工具,能够为决策者的循证决策提供参考依据。梳理了国内外卫生技术评估的程序及内容,回顾了卫生技术评估在国内外健康保险和健康管理领域的应用现状和进展,提出了新时期背景下卫生技术评估应明晰关键角色定位、回归评估目标价值、重视患者参与、保证独立客观、合理使用大数据等发展新要求,同时针对我国卫生技术评估存在的问题,结合国际经验提出了规范设计评估流程、促进决策转化、加强多方交流、提升循证决策意识、保障评估公正透明等相关建议,为促进卫生技术评估在健康保险和健康管理中的应用提供科学依据。

关键词: 卫生技术评估, 健康保险, 健康管理, 决策, 应用

Abstract: As an important health decision-making tool, health technology assessment(HTA)is used to provide scien- 山东大学学报 (医学版)57卷8期 -方亚. 卫生技术评估在健康保险和健康管理中的应用 \=-tific basis for policy-makers. This paper combs the progress of international and domestic application of HTA, summarizes the procedure and content, reviews the current status and progress of HTA in health insurance and health management, and puts forward new requests for HTA to meet the needs of time. In view of existing problems of HTA in China, this paper puts forward policy recommendations for further development, such as designing scientific evaluation process system, promoting the transformation of decisions, strengthening multilateral exchanges, promoting awareness of evidence-based decision making, ensuring the authority and transparency of HTA. Furthermore, it provides scientific basis for promoting the application of HTA in health insurance and health management.

Key words: Health technology assessment, Health insurance, Health management, Decision making, Application

中图分类号:

R197.1

方亚. 卫生技术评估在健康保险和健康管理中的应用[J]. 山东大学学报 (医学版), 2019, 57(8): 61-68.

FANG Ya. Application of health technology assessment in health insurance and health management[J]. Journal of Shandong University (Health Sciences), 2019, 57(8): 61-68.

参考文献

[1] 陈英耀,刘文彬,唐檬,等.我国卫生技术评估与决策转化研究概述[J].中国卫生政策研究,2013,6(7):1-6. CHEN Yingyao, LIU Wenbin, TANG Meng, et al. Introduction to knowledge translation from health technology assessment to health policy in China[J]. Chinese Journal of Health Policy, 2013, 6(7):1-6.
[2] 王海银,何达,王贤吉,等.国内外卫生技术评估应用进展及建议[J].中国卫生政策研究,2014,7(8):19-23. WANG Haiyin, HE Da, WANG Xianji, et al. Progress and recommendations for international and domestic application of health technology assessments[J]. Chinese Journal of Health Policy, 2014, 7(8):19-23.
[3] 谭晓东,祝淑珍,谢棚印,等.“健康中国”背景下健康管理的发展思路[J].公共卫生与预防医学,2015,26(6):1-4.
[4] 唐檬,耿劲松,刘文彬,等.全球卫生技术评估发展的历史与经验[J].中国医院管理,2014,34(4):6-9. TANG Meng, GENG Jinsong, LIU Wenbin, et al. History and experience of the development of health technology assessment in the world[J]. Chinese Hospital Management, 2014, 34(4):6-9.
[5] 金春林,王海银,陈洁.卫生技术评估方法、应用与发展建议[J].中国卫生资源,2014,17(1):24-25. JIN Chunlin, WANG Haiyin, CHEN Jie. Methods, applications and recommendations for health technology assessment[J]. Chinese Health Resources, 2014, 17(1):24-25.
[6] 刘鹏程,陈英耀.卫生技术伦理学评估与卫生决策[J].医学与哲学,2013,34(12):12-14. LIU Pengcheng, CHEN Yingyao. Health technology ethics assessment and health decisions[J]. Medicine and Philosophy, 2013, 34(12):12-14.
[7] Sean D, John W, Brian S, et al. Health technology assessment in health-care decisions in the United States[J].Value in Health, 2009, 12(2):39-43.
[8] Xie F, Bowen JM, Sutherland SC, et al. Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective[J]. Expert Rev Pharmacoecon Outcomes Res, 2011, 11(5):513-521.
[9] 张曙欣,陈校云,黄婉茹,等.加拿大循证决策支持程序及对我国的启示[J].中国卫生信息管理杂志,2018,15(2):152-155.
[10] 隋宾艳,齐雪然.英国NICE卫生技术评估研究决策转化机制及对我国的启示[J].中国卫生政策研究,2015,8(7):4157-4161. SUI Binyan, QI Xueran. Experience from translation mechanisms in the NICE health technology assessment to NHS decision making[J]. Chinese Journal of Health Policy, 2015, 8(7):4157-4161.
[11] 徐文煜,薛迪.美国、加拿大与澳大利亚的卫生技术评估[J].中国卫生质量管理,2011,18(1):8-10. XU Wenyu, XUE Di. Health technology assessment in United States, Canada and Australia[J]. Chinese Health Quality Management, 2011, 18(1):8-10.
[12] 茅艺伟,陈英耀,唐檬,等.澳大利亚卫生技术评估的应用[J].中国卫生资源,2014,17(6):484-486. MAO Yiwei, CHEN Yingyao, TANG Meng, et al. The application of health technology assessment in Australia[J]. Chinese Health Resources, 2014, 17(6):484-486.
[13] Briggs AK, Claxton MS. Descision modelling for health economic evalution[R]. London:Oxford University Press, 2006.
[14] 李滔,王秀峰,赵坤.英国卫生体制对我国医改的启示[J].中国全科医学,2015,18(34):4157-4161. LI Tao, WANG Xiufeng, ZHAO Kun. Enlightenment of British health system on the health system reform of China[J]. Chinese General Practice, 2015, 18(34):4157-4161.
[15] Hugh A, Ruth R, John A, et al. Better value in the NHS: the role of changes in clinical practices[EB/OL].(2015-07-07)[2018-09-17]. https://www.kingsfund.org.uk/publications/better-value-nhs.
[16] 刘佳琦,陈英耀. 新加坡、韩国和日本卫生技术评估发展概况及启示[J].中国卫生质量管理,2011,18(1):14-16. LIU Jiaqi, CHEN Yingyao. Development of health technology assessment in Singapore, South Korea and Japan:overview and implications for China[J]. Chinese Health Quality Management, 2011, 18(1):14-16.
[17] 陈致远,蒋蓉,邵蓉.台湾地区二代健保改革对大陆医保基金公平性及可持续性的启示[J].中国卫生政策研究,2017,10(2):50-56. CHEN Zhiyuan,JIANG Rong,SHAO Rong. Revelation of the second-generation national health care reform in Taiwan area on the equity and sustainability of the medicare fund in mainland China: the Care Chronicmodel[J]. Chinese Journal of Health Policy, 2017, 10(2):50-56.
[18] Health Information and Quality Authority. Health technology assessment of chronic disease self-management support interventions[EB/OL].(2015-12-16)[2018-09-17]. https://www.hiqa.ie/reports-and-publications/health-technology-assessments.
[19] Steuten L, Vrijhoef B, Severens H, et al. Are we measuring what matters in health technology assessment of disease management? Systematic literature review[J]. Int J Technol Assess Health Care, 2006, 22(1):47-57.
[20] Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model[J]. JAMA, 2002, 288(15):1909-1914.
[21] Ondrrˇej G, Ivana J, Radka O. Lecture notes in bioinformatics[C]. Switzerland: Springer International Publishing, 2015:54-65.
[22] 牛文芳,赵德明,许樟荣,等. 2型糖尿病患者强化管理的长期成本效果评价:长期花费与预后的模型研究[J].中国糖尿病杂志,2011,19(8):595-599. NIU Wenfang, ZHAO Deming, XU Zhangrong, et al. Evaluating the long-term cost-effectiveness ratio of intensive glycaemic control versus conventional glucaemic control in patients with type 2 diabetes mellitus: a modeling study of long-term costs and health outcomes[J]. Chinese Journal of Diabetes, 2011, 19(8):595-599.
[23] 陈云.基层社区医院对糖尿病患者实施规范化管理的临床效果与治疗成本[J]. 中国全科医学,2010,13(11):3771-3773. CHEN Yun. The clinical evaluation and treatment cost of the diabetic patients after standardized management in basic community[J]. Chinese General Practice, 2010, 13(11):3771-3773.
[24] 张琼.成都市社区老年人慢病管理服务质量评价[D]. 成都:四川大学,2007.
[25] 李文玲,王媛,李文,等.高血压电话访问式健康管理模式成本效果分析[J].中国全科医学,2014,17(28):3375-3377. LI Wenling, WANG Yuan, LI Wen, et al. Cost-effectiveness analysis of telephone interview model of health management of hypertension[J]. Chinese General Practice, 2014, 17(28):3375-3377.
[26] 梁小华.高血压社区健康管理卫生经济学评价及糖尿病手机管理效果评价研究[D]. 北京:北京协和医学院,2011.
[27] 吕曦.糖尿病社区干预等效果及成本效果研究[D].上海:复旦大学,2010.
[28] 曾雁冰,陈乐乐,黄晓玲,等.厦门市慢性病分级诊疗模式现状分析及效果评价[J]. 中华全科医师杂志, 2017, 16(11): 851-856. ZENG Yanbing, CHEN Lele, HUANG Xiaoling, et al. Understanding of hierarchical medical mode in chronic diseases management among medical staff and residents in Xiamen[J]. Chinese Journal of General Practitioners, 2017, 16(11): 851-856.
[29] 曾雁冰,陈帆,吴杰龙,等.慢性病分级诊疗“三师共管”知信行影响因素分析[J].中华医院管理,2017,33(6): 408-413. ZENG Yanbing, CHEN Fan, WU Jielong, et al. Research on the KAP influencing factors for the “Three-manager mode” in hierarchical medical system for chronic diseases[J]. Chinese Journal of Hospital Administration, 2017, 33(6):408-413.
[30] 胡萍,唐晓君,杨雪巍,等.中国农村糖尿病防治卫生技术的文献调查与分析[J].中国循证医学杂志,2015,15(6):713-738. HU Ping, TANG Xiaojun, YANG Xuewei. Literature investigation and analysis of the health technologies on diabetes prevention and management in rural China[J]. Chin J Evid-based Med, 2015, 15(6):713-738.
[31] 金娅娜,冷冰,张帆,等.中国农村心脑血管疾病卫生技术评估的系统评价[J].中国循证医学杂志,2015,15(3):276-281. JIN Yana, LENG Bing, ZHANG Fan. Health technology assessments on cardiovascular and cerebrovascular diseases among rural China: a systematic review[J]. Chin J Evid-based Med, 2015,15(3):276-281.
[32] Facey K, Henshall C, Sampietro-Colom L,et al. Improving the effectiveness and efficiency of evidence production for health technology assessment[J]. Int J Technol Assess Health Care, 2015, 31(4):201-206.
[33] Chen Y, Schweitzer SO. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region[J].Value Health, 2008(Suppl 1):S124-9.
[34] 国家科技评估中心.科技评估规范[M].北京:中国物价出版社,2001:1-5.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed